Drug Trial Radar · NCT03645928
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
225
Actual
Start
May 7, 2019
Primary completion
Feb 20, 2026
Study completion Feb 20, 2026
Sponsor
- Lead sponsor
- Iovance Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.
Conditions
- Metastatic Melanoma
- Squamous Cell Carcinoma of the Head and Neck
- Non-small Cell Lung Cancer
Interventions
LifileucelBiological
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor-infiltrating lymphocytes (TIL). After NMA-LD, patients receive lifileucel, followed by aldesleukin administration. Lifileucel will be administered to patients once (on Day 0) during the study.
LN-145Biological
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by aldesleukin administration. TIL will be administered to patients once (on Day 0) during the study.
PembrolizumabDrug
Humanized antibody. Pembrolizumab will be administered after tumor resection and will continue every 3 weeks or every 6 weeks for up to 2 years.
LN-145-S1Biological
A tumor sample is resected from each patient and cultured ex vivo to expand the population of TIL, then TIL with high levels of PD-1 surface expression are selected. After NMA-LD, patients receive their autologous PD-1-selected TIL (LN-145-S1), followed by aldesleukin administration. TIL will be administered to patients once (on Day 0) during the study.
IpilimumabDrug
Monoclonal antibody Ipilimumab will be administered as a single dose prior to tumor resection.
NivolumabDrug
Monoclonal antibody. Nivolumab will be administered once prior to tumor resection. The second dose will be administered prior to starting NMA-LD and will continue every 4 weeks for up to 2 years.
Nivolumab-relatlimabDrug
Monoclonal antibody (nivolumab) and monoclonal antibody (relatlimab). Nivolumab-relatlimab will be administered after tumor resection and will continue every 4 weeks for up to 2 years.
CisplatinDrug
Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
CarboplatinDrug
Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
PaclitaxelDrug
Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Nab paclitaxelDrug
Nab-Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
PemetrexedDrug
Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if applicable.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: Up to 60 months
- Safety Profile Measured by Grade ≥3 TEAEsTime frame: Up to 60 months
- Percentage of patients for whom lifileucel is successfully manufactured and meets release specificationTime frame: Up to 60 months
Locations
34 sites in 7 countries. Site status is shown where the registry gives one.
University of California, San Diego
La Jolla, California
University of Southern California
Los Angeles, California
University of California, Los Angeles
Los Angeles, California
University of Colorado
Denver, Colorado
Yale University
New Haven, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
Orlando Health Cancer Institute
Orlando, Florida
Moffitt Cancer Center
Tampa, Florida
University of Louisville
Louisville, Kentucky
University of Maryland
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Henry Ford Health System
Detroit, Michigan
MD Anderson at Cooper
Camden, New Jersey
Morristown Medical Center
Morristown, New Jersey
Memorial Sloan Kettering Cancer Center
New York, New York
University of Cincinnati
Cincinnati, Ohio
Ohio State University
Columbus, Ohio
Fred Hutchinson Cancer Research Center
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Lübeck, Schleswig-Holstein, Germany
Laiko General Hospital of Athens
Athens, Attica, Greece
Attikon University General Hospital
Athens, Attica, Greece
ICO l'Hospitalet - Hospital Duran i Reynals
Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain
Hospital Regional Universitario de Malaga - Hospital General
Málaga, Málaga, Spain
Universitaetsspital Bern
Bern, Switzerland
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
Guy's Hospital
London, England, United Kingdom
The Royal Marsden NHS Foundation Trust
London, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.